Category: Industry News

People Living with FSHD Speak to the FDA About the Disease’s QOL Effects

The FSHD Society held a landmark meeting recently in which individuals and families living with facioscapulohumeral muscular dystrophy (FSHD) told representatives from the US Food and Drug Administration (FDA) about how the muscle-wasting disease affects their health, and what they hope future treatments will do to improve their quality of life.

Read More